Lilly CEO calls for a 'wave of Invention' to reduce the toll of diabetes
In a speech to the Cleveland Clinic Medical Innovation Summit yesterday, John Lechleiter, chairman, president and chief executive of US drug major Eli Lilly (NYSE: LLY) described the "paradox of progress" against diabetes, noting that "for all our progress in treating diabetes, our ultimate goal seems as far away as ever." He called for a new "wave of invention" to combat the disease.
"Breakthroughs against diabetes are just as urgently needed today as they were a century ago," Dr Lechleiter said, adding that current trends suggest that one in every three Americans could have type 2 diabetes by 2050, up from one in 10 Americans who live with the disease today. "As we all know, this is a health and economic time bomb," said Lechleiter, noting that diabetes is the leading cause of new cases of blindness, kidney failure, and non-traumatic amputations, as well as a leading contributor to heart disease and stroke.
Lilly’s involvement in diabetes treatment
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze